<DOC>
	<DOCNO>NCT02924753</DOCNO>
	<brief_summary>This study patient previously treat B-ALL . The purpose study determine safety feasibility CART-19 cell patient relapse refractory CD19+ B-ALL .</brief_summary>
	<brief_title>The Safety Efficacy CART-19 Cells B-cell Acute Lymphoblastic Leukemia ( B-ALL ) .</brief_title>
	<detailed_description>Subjects stag suitability T cell CART-19 manufacturing determine entry phase , . Subjects collect large number peripheral blood mononuclear cell ( PBMC ) CART-19 manufacturing . The T cell purify PBMC , transduce CART-19 lentiviral vector , expand vitro administer subject . Subjects blood test assess safety efficacy , persistence CART-19 cell regular interval four week last infusion study . Following 6 month intensive follow-up , subject evaluate quarterly two year physical examination , blood test , bone marrow aspirate , minimal residual disease ( MRD ) persistence CART-19 . Following evaluation , subject evaluate health problem every year additional thirteen year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>1 . 4 year 70 year , expect survival &gt; 3 month 2 . CD19 positive Bcell acute lymphoblastic leukemia 3 . Karnofsky Performance Status ( KPS ) &gt; 70 4 . Relapsed allogeneic autologous stem cell transplantation ( SCT ) ; 5 . Cardiac function : 12 level ; Liver : TBIL≤3 Upper Limit Normal ( ULN ) ，aspartate aminotransferase ( AST ) ≤2.5 ULN，ALT ≤2.5 ULN ; kidney : Cr≤1.25 ULN ; bone marrow : White Blood Cell ( WBC ) ≥ 3.0×109/L , Hb ≥90 g/L , Platelet ( PLT ) ≥ 80×109/L） 6 . No serious allergic constitution 7 . No serous disease conflict clinical program 8 . No cancer history 9 . No serious mental disorder 10 . Informed consent sign subject lineal relation . 1 . Pregnant lactating woman ; ( female participant reproductive potential must negative serum urine pregnancy test ) 2 . Uncontrolled active infection , HIV infection , syphilis serology reaction positive 3 . Active hepatitis B hepatitis C infection 4 . Recent current use glucocorticoid immunosuppressor 5 . With severe cardiac , liver , renal insufficiency , diabetes disease 6 . Transaminase &gt; 2.5 ULN , Bilirubin &gt; 3 ULN，Creatinine &gt; 1.25 ULN 7 . Participate clinical research past three month ; previously treatment gene therapy product 8 . Researchers think fit participate study , case affect clinical trial result</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>